key: cord-0979202-jo16yimu authors: Pande, Monu; Kundu, Debanjan; Srivastava, Ragini title: Drugs repurposing against SARS-CoV2 and the new variant B.1.1.7 (Alpha Strain) targeting the spike protein: Molecular docking and Simulation studies date: 2021-08-17 journal: Heliyon DOI: 10.1016/j.heliyon.2021.e07803 sha: a7b750b08338343a13533fda60498a0af8a2440f doc_id: 979202 cord_uid: jo16yimu Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) is responsible for the global COVID-19 pandemic and millions of deaths worldwide. In December 2020, a new alpha strain of SARS-CoV2 was identified in the United Kingdom. It was referred to as VUI 202012/01 (Alpha strain modelled under investigation, 2020, month 12, number 01). The interaction between spike protein and ACE2 receptor is a prerequisite for entering virion into the host cell. The present study is focussed on the spike protein of the SARS-COV 2, involving the comparison of binding affinity of new alpha strain modelled spike with previous strain spike (PDB ID:7DDN) using in silico molecular docking, dynamics and simulation studies. The molecular docking studies of the alpha strain modelled spike protein confirmed its higher affinity for the ACE2 receptor than the spike protein of the dominant strain. Similar computational approaches have also been used to investigate the potency of FDA approved drugs from the ZINC Database against the spike protein of new alpha strain modelled and old ones. The drug molecules which showed strong affinity for both the spike proteins are then subjected to ADME analysis. The low overall binding energy of Conivaptan (-107.503 kJ/mol) and Trosec (-94.029 kJ/mol) is indicative of their strong binding affinities, well supported by interactions with critical residues. has two functional subunits S1 and S2, responsible for host recognition and entrance into host CoV2 spike protein has multiple furin cleavage sites, which make it susceptible to cleavage by 141 host cell protease into S1 and S2 subunits. This cleavage facilitates the fusion of the viral 142 membrane with the host cell membrane and allows the viral genome's entry into the host cell 143 [16] . All these features make the SARS CoV-2 more contagious than SARS-CoV. The sense 144 RNA of CoVs is susceptible to frequent mutation and recombination and, therefore, is 145 recognised as immensely evolving viruses. 146 In the fall of 2020, a new alpha strain of SARS-CoV2 was identified in the United Kingdom. 147 It has been referred to as VUI 202012/01(Alpha strain modelled under investigation, 2020, protein of SARS-CoV2. These are alanine to aspartic acid, proline to histidine, threonine to study focuses on the spike protein of the SARS-COV-2, involving the binding affinity of 163 potential drugs against the new alpha strain compared to the previous strain using in silico 164 molecular docking. In the present study, the PDB ID 7DDN represents the spike protein of the 165 previous strain as it was the most recent structure submitted to Protein Data Bank when the 166 study was carried out. The spike protein of the alpha strain was modelled by including all the 167 mutations in the previous strain. Similar computational approaches have also been used to 168 investigate the potency of FDA-approved drugs from the ZINC Database or from other 169 Databases against the spike protein, although mainly against the original Wuhan strain. These To see the effect of these mutations on the overall morphology and function of the modelled 308 spike protein, including any preferential changes in its interaction with ACE2 receptors and 309 with other ligand molecules (here FDA approved Drug molecules), we modelled the entire 310 spike protein comprising all the mutations. We compared the structure and affinity of a 311 modelled spike of alpha strain for ACE2 and drug molecules of ZINC database than spike 312 protein of dominant strain (7DDN-PDB ID). 313 We used the 6Z97.1.A template for modelling the 3D structure of the spike protein (Fig 2A) of (Fig.S1 ). As we have used the 6Z97 structure as a template for modelling the spike protein of 330 alpha strain, whereas for the rest of comparative studies, we are using 7DDN structure, 331 therefore to avoid any discrepancy, the single chain of 7DDN was superimposed on the 6Z97 332 structure (Fig.S2 ) 333 We superimposed the modelled alpha strain spike with 7DDN spike for the trimeric and single-334 A chain structures (Fig 3A & 3B) . The structural analysis revealed that sequences from on the trimeric structure of 7DDN spike, we found that the RBD of 6lzg structure entirely 349 coincides with the RBD of a single chain of the trimeric spike (Fig.S3, S10) . Table 4 and Table 5 , respectively. Overall, the drugs used 440 in this study successfully qualified the filtering criteria based on Lipinski's rule of five and 441 follow the ADME properties for being a potent orally active drug. 443 We performed molecular dynamics of the modelled spike apoprotein of alpha strain and the Ecamsule also showed one violation of the rule, but still, its complex with the alpha strain 448 modelled spike proceeded for molecular dynamics simulation as it has the highest binding (Fig 7A & B) . 473 The Radius of gyration trajectory of all three complexes agrees with the RMSD trajectories. and Conivaptan complexes have much lower average RMSF in the total protein compared to 487 the apoprotein. We further highlighted the RMSF of the most critical residues for ligand 488 interaction in the alpha strain modelled spike protein's receptor-binding motif (Fig.8 A-D) . The Table S1 . 520 We performed MM/PBSA free energy analyses for two of our complexes: Conivaptan and 521 Trosec. We performed the energy analyses in the respective complexes once the systems were 522 stabilised. Conivaptan free energy analysis was performed between 30-50 ns, and Trosec free 523 energy analysis was performed between 50-60ns. In both cases, energy was calculated at every domain with the ACE2 receptor is a crucial strategy for drug development in this case [65] . 550 An essential objective of the present study is to inhibit or decrease the interaction frequency has been started in many countries, it will still take a long time to complete. Therefore, the 600 search for effective drugs against this constantly mutating virus will be essential to control to 601 avert any potential outbreak again. Repurposing drugs will be a valuable strategy to combat 602 such a high rate of transmission and mortality associated with some strains of SARS CoV2 and 603 will be of high priority. Drug development against viral infections remain one of the most 604 elusive challenges of medical biotechnology, and we must strive forward towards the ever-605 growing challenge with a sound literature background. Amino acid sequence from 828-843 of alpha strain modelled spike is in orange sticks. B. Superimposed 3D structure of alpha strain modelled spike (Magenta) and 7DDN spike (Cyan). All the figures are generated in PyMol software. Identification of a novel coronavirus in patients with severe acute respiratory syndrome Cryo-electron 616 microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite 617 conformational state for receptor binding Emerging Coronaviruses: Genome Structure, replication 619 and pathogenesis 418 SARS and MERS: 621 recent insights into emerging coronaviruses Epitope based peptide vaccine design and target site depiction against Middle East 625 Respiratory Syndrome Coronavirus: an immune informatics study A novel coronavirus 628 from patients with pneumonia in China A new coronavirus 631 associated with human respiratory disease in China Comparative analyses of SAR-CoV2 634 genomes from different geographical locations and other coronavirus family genomes 635 reveals unique features potentially consequential to host-virus interaction and 636 pathogenesis The coronavirus spike 638 protein is a class I virus fusion protein: structural and functional characterisation of the 639 fusion core complex Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. 643 Structure of SARS coronavirus spike 645 receptor-binding domain complexed with receptor 647 (2020) Structural Basis of Receptor Recognition in SARS CoV 2 Identification of SARS CoV 2 cell entry 649 inhibitors by Drug Repurposing using In silico structure-based Virtual Screening The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like 660 cleavage site absent in CoV of the same clade SARS-CoV-2 lineages A 663 dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic 664 epidemiology Rapid increase of a SARS-CoV-2 alpha strain modelled with multiple spike protein 666 mutations observed in the United Kingdom Alpha strain modelled coronavirus in the United Kingdom sets off alarms, but its 668 importance remains unclear TL BLAST+: architecture and applications HH-suite3 for fast remote homology detection and deep protein annotation Automated comparative protein structure 675 modelling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective QMEAN DisCo-distance constraints applied on model quality 678 estimation PROCHECK: Validation 680 of protein structure coordinates Crystallography of Biological Macromolecules MolProbity: All-atom structure validation for macromolecular 684 crystallography 7DDN SARS-Cov2 S protein at open state 686 ZINC: 688 a free tool to discover chemistry for biology Open Babel: An open chemical toolbox UCSF Chimera--a visualisation system for exploratory research 693 and analysis The ClusPro web server for protein-protein docking How good is automated protein docking? Discovery Studio Visualiser PLIP: fully automated protein-ligand interaction profiler PyDeT, a PyMOL plug-in for visualising geometric concepts around 706 proteins SWISS-MODEL: An automated 708 protein homology-modeling server Virtual 710 screening of approved drugs as potential SARS CoV2 main protease inhibitors Biol Identification of high affinity 713 and low molecular alternatives of boceprevir against SARS CoV2 main protease: A 714 virtual screening approach Molecular and clinical insights into protein misfolding and 716 associated amyloidosis Bacterial protein azurin 719 and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular 720 docking and molecular dynamics simulations Vitamin C and Vitamin D3 show strong binding 723 with the amyloidogenic region of G555F alpha strain modelled of Fibrinogen A 724 alpha-chain associated with renal amyloidosis: proposed possible therapeutic 725 intervention Predicting crystal structures: the Parrinello-727 Rahman method revisited LINCS: a linear constraint 729 solver for molecular simulations L (2020) α-Glucosidase inhibitory 732 effect of anthocyanins from Cinnamomum camphora fruit: Inhibition kinetics and 733 mechanistic insights through in vitro and in silico studies In vitro and MD 736 simulation study to explore physicochemical parameters for antibacterial peptide to 737 become potent anticancer peptide, Molecular Therapy-Oncolytics 16; 7-19. throughput MM-PBSA calculations Structure validation by Calpha geometry: Phi, psi and Cbeta 741 deviation PROCHECK: validation of 743 protein structure coordinates ACE2 X-ray structures reveal a large hinge-bending motion 747 important for inhibitor binding and catalysis Photostability assessment of sunscreens. Benzylidene 749 camphor and dibenzoylmethane derivatives PubChem Compound Summary for CID 752 54732242 Pharmacognosy of Ergot (Argot or St. Anthony's Fire)". pharmaxchange.info CAFERGOT-ergotamine tartrate and caffeine tablet, film-coated". DailyMed. US 757 National Library of Medicine Ponatinib Wins Early FDA Nod Conivaptan: Evidence supporting its therapeutic use 763 in hyponatremia Pimozide: use in Tourette's syndrome Trospium chloride treatment of overactive bladder SwissADME: a free web tool to evaluate 770 pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small 771 molecules Experimental and 773 computational approaches to estimate solubility and permeability in drug discovery and 774 development settings Beyond the Rule of 5: 776 Lessons Learned from AbbVie's Drugs and Compound Collection MAb cocktail for treating SARS-CoV-2 infections Promising terpenes as 783 SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the 784 human ACE2 receptor: Integrated computational approach Plant Products as Inhibitors of Coronavirus 3CL Identification of new anti-789 nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main 790 protease as target Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-793 Identification of a repurposed drug as 795 an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational 796 methods Repurposing of 798 FDA Approved Drugs for the Identification of Potential Inhibitors of SARS Cambridge: Cambridge Open Engage Several FDA-Approved Drugs Effectively 801 Inhibit SARS-CoV-2 Infection in vitro Potential SARS-CoV-2 protease 803 M pro inhibitors: repurposing FDA-approved drugs Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 Mpro Drug Repurposing for Candidate 809 SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method. Molecules Silico 812 Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV Alpha strain modelleds with a Focus at the ACE2-Spike RBD Interface Automated docking of flexible ligands: applications 816 of AutoDock UCSF Chimera--a visualisation 818 system for exploratory research and analysis